CompletedPHASE1, PHASE2NCT01833520

Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

Studying Bone sarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Vivek Subbiah, MD
M.D. Anderson Cancer Center
Intervention
Ra-223 Dichloride(drug)
Enrollment
18 target
Eligibility
15 years · All sexes
Timeline
20132020

Study locations (1)

Collaborators

Bayer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01833520 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma

← Back to all trials